Cardiovascular Diseases Research Group (BIO-HEART)

Summary

This group focusses on clinical research in the area of cardiovascular diseases and risks, and has extensive experience in a highly relevant field, as cardiovascular diseases remain the main cause of mortality among both women and men in the Western world.
The group studies new surgical and pharmacological treatments for improving survival and recovery of patients affected by these diseases. It has extensive experience in the study of drugs which prevent platelet aggregation in the blood, specifically.

2089

Publications

Strategic lines

Selected Publications

Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM, DELIVER Trial Committees and I. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N. Engl. J. Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286.

Senage T, Paul A, Le Tourneau T, Fellah Hebia I, Vadori M, Bashir S, Galinanes M, Bottio T, Gerosa G, Evangelista A, Badano LP, Nassi A, Costa C, Cesare G, Manji RA, de Monchy CC, Piriou N, Capoulade R, Serfaty JM, Guimbretiere G, Dantan E, Ruiz Majoral A, du Fou GC, Ben Arye SL, Govani L, Yehuda S, Abramovitch SB, Amon R, Reuven EM, Atiya Nasagi Y, Yu H, Iop L, Casos K, Kuguel SG, Blasco Lucas A, Permanyer E, Sbraga F, Llatjos R, Moreno Gonzalez G, Sanchez Martinez M, Breimer ME, Holgersson J, Teneberg S, Pascual Gilabert M, Nonell Canals A, Takeuchi Y, Chen X, Manez R, Roussel JC, Soulillou JP, Cozzi E, Padler Karavani V. The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration. Nat. Med. 2022;28(2):283-294. doi:10.1038/s41591-022-01682-w.

Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat. Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1.

Moliner P, Comin Colet J. Iron deficiency and supplementation therapy in heart failure. Nat. Rev. Cardiol. 2022;19(9):571-572. doi:10.1038/s41569-022-00747-0.

Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, Comin Colet J, Ferreira JP, Mentz RJ, Nassif ME, Psotka MA, Tromp J, Brueckmann M, Blatchford JP, Salsali A, Voors AA. Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized for Acute Heart Failure - Results From the EMPULSE Trial. Circulation. 2022;146(4):279-288. doi:10.1161/CIRCULATIONAHA.122.059725.

Selected Projects

MCI21056. Estrategias preventivas integradoras para el cáncer y las enfermedades cardiovasculares basadas en inteligencia artificial (IA ) Ministerio de Ciencia e Innovación. Budget: 569250. 2022-2024. PI: Comín Colet, Josep.

MCI21056. TED 2021- CCSHARED - Artificial intelligence (AI) driven integrative preventive strategies for cancer and CV disease (ARTICCA). Ministerio de Ciencia e Innovación. Budget: 569250. 2022-2024. PI: Josep Comin."

18ACL013. Estudio Onyx ONE; un estudio aleatorizado y controlado con el stent Resolute Onyx y tratamiento de doble antiagregación plaquetaria [DAPT] de Un mes para pacientes con alto riesgo de sangrado. Budget: 350800. 2018- . PI: Cequier Fillat, Ángel.

20ACL119. HELIOS-B: ESTUDIO DE FASE 3, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE VUTRISIRÁN EN PACIENTES CON AMILOIDOSIS CARDIACA POR TRANSTIRETINA (AMILOIDOSIS POR ATTR CON MIOCARDIOPATÍA). Budget: 299745. 2020- . PI: González Costello, José.

MCI22001. Clinical trial to evaluate the administration of ApTOLL in Acute Myocardial Infarction. APSTEMI. Ministerio de Ciencia e Innovación. Budget: 259100,89. 2022-2025. PI: Gómez Hospital, Joan Antoni.